|Articles|June 1, 2003
- BioPharm International-06-02-2003
- Volume 2003 Supplement
- Issue 1
Part 1: Skin, Bone, and Cells
Author(s)Gail Sofer
by Gail Sofer, BioReliance
Advertisement
Articles in this issue
over 22 years ago
BioPharm International's Virus Inactivation Series: A Prefaceover 22 years ago
Part 4: Culture Media, Biotechnology Products, and Vaccinesover 22 years ago
Inactivation of Viruses: An Introduction to the Seriesover 22 years ago
Part 6: Inactivation Methods Grouped by Virusover 22 years ago
Part 5: Disinfectionover 22 years ago
Part 2: Red Blood Cells and PlateletsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Clears In-Vivo Gene Editing Therapy PBGENE-DMD for Duchenne Trial
2
VectorY Doses First Patient in TDP-43–Targeting ALS Trial
3
The Clinical Execution Gap: Why Great Science Often Fails at the Trial Stage
4
Women in STEM: Building Sustainable Cost and Access Models for Advanced Therapies (Part 1)
5
